Months after steering a seizure rescue therapy to market, UCB bags another promising late-stage asset for $125M upfront
UCB has picked up an epilepsy drug-device from a buyout that will cost at most $270 million, tucking a Phase III-ready project and the team behind it to its growing neurology portfolio.
While at least two benzodiazepines are already available as treatments for acute seizure, the Belgian pharma has been shopping for more convenient dosing methods that could prove superior to buccal midazolam and rectal diazepam.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 90,400+ biopharma pros reading Endpoints daily — and it's free.